OP
NAMS icon

ORG Partners’s NewAmsterdam Pharma NAMS Stock Holding History

ORG Partners’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$2.1K Buy
+60
New +$2.18K ﹤0.01% 1437

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

ORG Partners's NAMS Position: Q4 2025 in Review

ORG Partners opened a new position in NewAmsterdam Pharma (NAMS) in Q4 2025: 60 shares worth $2.1K. The stake represents ﹤0.01% of the portfolio and ranks #1437 among its holdings.

186 funds tracked by Wall St. Rank hold NAMS as of Q4 2025.

  • ORG Partners held 60 shares of NewAmsterdam Pharma worth $2.1K as of Q4 2025.
  • NewAmsterdam Pharma was a new ORG Partners position in Q4 2025.
  • NewAmsterdam Pharma made up ﹤0.01% of ORG Partners's portfolio in Q4 2025, its #1437 holding.
  • 186 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q4 2025.

Based on ORG Partners's 13F filing for Q4 2025, filed 14 Jan 2026.